| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Novadel Should End Relationship With Hana
Posted on 03/24/2007 19:55:01 | Link | Post Comment
by H.S. Ayoub
BioHealth Investor.com
Hana Biosciences (HNAB) announced today that the company will cancel its FDA filing for Zensana, and work with Novadel (NVD) to resubmit a filing for a European formulation of the treatment in 2008.
Back in February, Hana announced that a delay of FDA approval was caused by an unidentified precipitate during manufacturing of the U.S. formulation of Zensana.
HNAB is down more than 35% during mid-day trading on Friday, while Novadel is down less than 10%.
I still believe in Novadel, and think it has a bright future. As later on in 2007, other FDA filings are expected to be submitted for the company's other products. But untill then, I believe that there are other opportunities available in other stocks.
I have sold my shares of Novadel for the time being, and will keep on eye on the stock. If the company hits its target dates with the expected FDA filings later in 2007, and it looks like the target date for the re-filing of Zensana is on scheduale, then I may buy back in. Andrew Vaino seems to share my views.
I have taken the capital and invested it in shares of Bruker BioSciences (BRKR), which I have featured at BHI recently.
Personally, I believe that Novadel can do better than Hana, and I have said that before. I think Novadel should end its agreement with Hana and find a new partner, if any associated charges are not excessive.
RELATED READING:
- Novadel Drops After Zensana Launch Delayed by Hana Biosciences
- Are NovaDel and Pfizer Collaborating on a Viagra Spray?
- Novadel Stock Offering & Dilution
- Biotech Penny Stocks Novadel and Insmed
- NovaDel's Oral Spray Delivery Technology Looks Promising
_________________________
BioHealth Investor.com
Hana Biosciences (HNAB) announced today that the company will cancel its FDA filing for Zensana, and work with Novadel (NVD) to resubmit a filing for a European formulation of the treatment in 2008.
Back in February, Hana announced that a delay of FDA approval was caused by an unidentified precipitate during manufacturing of the U.S. formulation of Zensana.
HNAB is down more than 35% during mid-day trading on Friday, while Novadel is down less than 10%.
I still believe in Novadel, and think it has a bright future. As later on in 2007, other FDA filings are expected to be submitted for the company's other products. But untill then, I believe that there are other opportunities available in other stocks.
I have sold my shares of Novadel for the time being, and will keep on eye on the stock. If the company hits its target dates with the expected FDA filings later in 2007, and it looks like the target date for the re-filing of Zensana is on scheduale, then I may buy back in. Andrew Vaino seems to share my views.
I have taken the capital and invested it in shares of Bruker BioSciences (BRKR), which I have featured at BHI recently.
Personally, I believe that Novadel can do better than Hana, and I have said that before. I think Novadel should end its agreement with Hana and find a new partner, if any associated charges are not excessive.
RELATED READING:
- Novadel Drops After Zensana Launch Delayed by Hana Biosciences
- Are NovaDel and Pfizer Collaborating on a Viagra Spray?
- Novadel Stock Offering & Dilution
- Biotech Penny Stocks Novadel and Insmed
- NovaDel's Oral Spray Delivery Technology Looks Promising
_________________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home